The purpose of this study was to evaluate the feasibility and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen (RIST) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). In all, 36 patients (median age 55 years) underwent RIST from an HLA-matched related donor between September 1999 and December 2002. The diagnoses included AML (n ¼ 14), leukemia evolving from MDS (n ¼ 10), and MDS (refractory anemia with excess blasts n ¼ 6, refractory anemia n ¼ 6). The RIST regimen consisted of purine analog (cladribine or fludarabine)/busulfan, with or without antithymocyte globulin. The regimen was well tolerated, and 34 patients achieved durable engraftment and most achieved remission after RIST. A total of 17 patients developed grade II-IV acute GVHD, and 27 developed chronic GVHD. Eight patients relapsed, and five of them received antithymocyte globulin (ATG) as part of the preparative regimen. A total of 12 patients died (four disease progression, six transplantation-related complications, and two others). Estimated 1-year disease-free survival (DFS) in low-and highrisk groups was 85 and 64%, respectively. We conclude that RIST can be performed safely in elderly patients with myeloid malignancies, and has therapeutic potential for those who fail conventional chemotherapy. In view of the significant association between GVHD or ATG and DFS, defined management of GVHD following RIST should become a major target of clinical research.
Despite progress in the therapy of supportive care for acute myeloid leukemia (AML) over the past several decades, most patients relapse within the first 2 years of achieving complete remission (CR). Moreover, for the approximately 33% of patients who achieve a second remission, the median survival is only 18 weeks. 1 The median age of patients with AML is approximately 65 years, making it difficult to apply intensive chemotherapy to improve clinical outcome.
The natural history of myelodysplastic syndrome (MDS) ranges from a chronic course that may span years to very rapid leukemia progression. The morphological subtypes of MDS can generally be categorized into two risk groups based on outcomes.
2 The low-risk group includes refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS). The clinical course of low-risk MDS is usually protracted, with a median survival in excess of 60 months. 3 On the other hand, the high-risk group includes refractory anemia with excess blasts (RAEB-1 and RAEB-2) 4 and refractory cytopenia with multilineage dysplasia (RCMD), with or without ringed sideroblasts. The median survival is 33 months for RCMD, 18 months for RAEB-1, and 10 months for RAEB-2. 3 Few patients with high-risk MDS survive with cytotoxic chemotherapy alone. 5 Clinical and laboratory evidence has been reported regarding a graft-versus-leukemia (GVL) effect following allogeneic hematopoietic stem cell transplantation (allo-HSCT), 6, 7 which is now regarded as the treatment of choice for patients with advanced AML and MDS.
2 A small but significant proportion of patients with advanced AML or MDS can be cured with allo-HSCT. 8, 9 Allo-HSCT should be offered to those who have an HLA-identical donor. However, the substantial toxicity and treatment-related mortality associated with a conventional transplantation regimen limit its application to young patients, and the feasibility of allo-HSCT has not been fully established in elderly patients with AML and MDS.
Recently, a new strategy for transplantation using a reduced-intensity (RIST) or nonmyeloablative preparative regimen has been developed to reduce regimen-related toxicity (RRT) while preserving an adequate antitumor effect associated with allo-HSCT. 10, 11 Although preliminary data appear to be attractive, suitable widely acceptable regimens and indications for this strategy remain to be established. In particular, little information is available concerning the use of RIST for the treatment of advanced myeloid malignancies. Giralt et al reported the results of two feasibility studies on RIST for myeloid malignancies. 12, 13 In the first study, 12 they treated 31 patients with AML and four patients with MDS. CR was achieved in 24 patients, with a 1-year overall survival (OS) of 47% and disease-free survival (DFS) of 34%. In the second study, 13 they treated 34 patients with AML and nine patients with MDS. Of the 43 patients with AML/MDS, 26 achieved CR. The 1-year OS and DFS were 39 and 35%, respectively. These pilot studies suggest that long-term disease control can be achieved by RIST in patients with advanced myeloid malignancies who are not candidates for conventional HSCT.
In September 1999, we initiated a feasibility study of RIST using a cladribine-based preparative regimen. 14 Cladribine was replaced by fludarabine in November 2000, when the former drug was no longer available because of the limitations in insurance coverage in Japan. This report summarizes our findings regarding the safety and efficacy of RIST for myeloid malignancies.
Patients and methods

Patient characteristics
From September 1999 to December 2002, 36 consecutive patients with AML or MDS underwent RIST from an HLA-identical related donor (34 siblings, and two daughters). The median age was 55 years (range 27-67 years). These patients were considered to be ineligible for myeloablative HSCT because of their age (ie, older than 50; n ¼ 34), hepatic impairment (n ¼ 2), or cardiac dysfunction (n ¼ 3) including one aortic insufficiency due to EhlersDanlos syndrome. One patient with AML evolving from MDS had myeloablative HSCT before enrollment in this study. Diagnosis at transplantation included AML (n ¼ 24) and MDS (n ¼ 12). Detailed information on each patient is shown in Table 1 . Patients were classified into two risk groups according to disease status. Those with AML in first remission or MDS RA were defined as low risk, and the others were defined as high risk. Of the 24 patients with AML, 14 and 10 patients had de novo AML and AML evolving from MDS, respectively. At the time of enrollment, six of the 24 patients with AML were in first remission, seven in more than second remission, and the remaining 11 were not in remission. Six patients were categorized in the low-risk group and 18 in the high-risk group.
According to the WHO classification, 4 12 patients with MDS were classified as RA (n ¼ 6), RAEB-1 (n ¼ 3), and RAEB-2 (n ¼ 3). Four of the six patients with RA had failed to respond to immunosuppressive therapy including cyclosporine (n ¼ 3) and antithymocyte globulin (ATG; n ¼ 2) prior to transplantation. The other patients were treated with supportive therapy alone. Among the six patients with RAEB-1 or RAEB-2, three received cytarabine-based induction chemotherapy, and two of them achieved CR. The other three patients received RIST without receiving any cytotoxic chemotherapy prior to transplantation. Of the 12 patients with MDS, eight and four patients were categorized in the low-and high-risk group, respectively. Donor eligibility required an HLAmatched donor determined by serologic typing for HLA A, B, and DR. All patients and donors gave their written informed consent in accordance with the requirements of the Institutional Review Board of the National Cancer Center Hospital.
Preparative regimens
From September 1999 to October 2000, eight patients received a cladribine-based preparative regimen consisting of cladribine (Leustatin; Ortho Biotech, Raritan, NJ, USA) 0.11 mg/kg on days À10 to À4 and busulfan 4 mg/kg on days À6 and -5.
14 Seven of the eight patients also received rabbit ATG (Thymoglobulin; Imtix-Sangstat, Lyons, France) 2.5 mg/kg for 2 or 4 consecutive days. From November 2000 to December 2002, 28 patients received a fludarabine-based regimen consisting of fludarabine 30 mg/m 2 on days À8 to -3 and busulfan 4 mg/kg on days À6 and -5. 11 One of these 28 patients received additional ATG as described above.
Mobilization and collection of peripheral blood stem cells
Donors were given subcutaneous G-CSF at 400 mg/m 2 daily for 3 consecutive days. Leukapheresis was performed on the 4th day, and subsequent days if necessary, using conventional techniques for peripheral blood stem cells collection. Cells were cryopreserved with the traditional controlled-rate method of cryopreservation. Stored cells were thawed in a 371C water bath, and infused through a central or peripheral vein, without washing. The number of CD34 þ cells infused on day 0 ranged from 1.50 to 6.55 Â 10 6 cells/kg (median 2.85 Â 10 6 cells/kg).
GVHD
For GVHD prophylaxis, 30 patients received cyclosporine alone, 3 mg/kg, by continuous infusion starting on day À1. The other six patients received cyclosporine and short-term methotrexate at a dose of 10 mg/m 2 on day 1, and 7 mg/m 2 on days 3 and 6. Intravenous cyclosporine was switched to oral administration as soon as it became tolerable. GVHD was diagnosed by clinical judgment as well as skin or digestive tract biopsies to support the clinical diagnosis. Acute and chronic GVHD were graded according to the consensus criteria. 15, 16 When patients developed grade II-IV acute GVHD, our practice was to initiate 2 mg/ kg/day methylprednisolone in addition to cyclosporine. Patients who survived 100 days or longer after transplantation were included in the analysis of chronic GVHD.
Supportive care
All of the patients were managed in reverse isolation in a laminar airflow-equipped room, and received routine antibacterial, antifungal, and antiviral prophylaxis, which These counts were collected prior to preparative regimen.
RIST in patients with myeloid malignancies T Hamaki et al included trimethoprim/sulfamethoxazole or pentamidine, fluoroquinolone, and fluconazole for the prophylaxis of pneumocystis carinii, bacterial, and fungal infection, respectively: five patients with prior histories of pulmonary aspergillus infections received amphotericin B. Prophylaxis of herpes virus infection using acyclovir has been reported previously. 17 Neutropenic fever was managed as reported previously. 18 All patients were monitored weekly by CMV pp65 antigenemia. If the antigenemia assays were positive, pre-emptive therapy with ganciclovir was initiated. 19 
Chimerism analysis
Chimerism of CD3-positive cells in peripheral blood was assessed every 30 days. Variable number of tandem repeats (VNTR) PCR was used to document engraftment or residual host-type cells, with residual host or donor cells detected at a sensitivity of 5%. 20 The values are given as a percentage of donor signals. /l for 7 days without receiving transfusion. Graft rejection was defined as peripheral blood aplasia and marrow hypoplasia 421 days after transplantation, with no evidence of donor markers as revealed by cytogenetic and molecular techniques.
Regimen-related toxicities
All nonhematological organ dysfunctions from day 0 to day 28 were considered to be RRT, and were graded according to Bearman et al's criteria. 21 Pulmonary dysfunction was additionally evaluated on day 100 after RIST. Transplantation-related mortality (TRM) was defined as death directly caused by the transplantation procedure.
End points and statistical analysis
The primary end points of this study included durable hematopoietic engraftment and TRM. Secondary end points included RRT, the incidence and severity of GVHD, DFS, and OS. Responses to transplantation were defined according to the recommendations of the international working group. 22 An analysis of acute GVHD was performed for patients who achieved initial engraftment. An analysis of chronic GVHD was performed for those who survived 100 days or longer. The probabilities of OS and DFS were calculated as a function of time using the Kaplan-Meier method from the date of stem cell infusion (day 0). DFS was also calculated from the day of transplantation because all of the recipients were in CR when they achieved engraftment. Disease was defined as the day of relapse or death. Surviving patients were censored on the last day of follow-up. These data were calculated as of April 20, 2003 .
Results
Engraftment and chimerism
While one patient had full autologous reconstitution with blasts before achieving the primary endpoints, the other 35 patients achieved engraftment. The median time for ANC to reach 0.5 Â 10 9 /l was 13 days. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Platelet counts did not decrease below 20 Â 10 9 /l in one patient. In the remaining 34 patients, the median time for platelet recovery to increase above 20 Â 10 9 /l without platelets transfusion was 18 days. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] One patient (patient 6) developed late graft failure due to septicemia, and finally died of multiple organ failure on day 78. Overall, graft failure developed in two of the 28 patients.
A total of 32 patients were evaluated with chimerism analysis using cytogenetic or molecular techniques. The median percentage of donor CD3-positive cells at the first examination (30 days after transplant) was 86% (range 40-100). In all, 15 patients achieved complete donor chimerism, and 17 patients had mixed chimerism at day 30. Of these 17 patients, 14 finally converted into complete chimerism by day 120 with a reduction in the dose of cyclosporine or observation. The other three patients showed prolonged mixed chimerism, one after late graft failure.
Regimen-related toxicities
RRTs are summarized in Table 2 . The RIST regimens were tolerated well, and most toxicity was temporary and reversible. Liver toxicity was the most common complication following RIST. In all, 21 patients (58%) developed hepatic toxicity within 28 days of transplant. Neither grade 3-4 hepatic toxicity nor veno-occlusive disease of the liver was seen in any of the patients.
One patient developed congestive heart failure on day 14, corresponding to grade 3 cardiac toxicity (patient 6). Since this patient's cardiac function had been impaired before transplant, the relationship between the preparative regimen and development of heart failure was unclear. The patient developed grade 3 toxicities of the liver and the central nervous system, resulting in TRM on day 78. Table 2 Regimen-related toxicity The incidence of TRM within 100 days of transplant was 2.7%.
Infectious complications
Neutropenic fever requiring the empiric use of antibiotics occurred in 11 patients (30%). Bacterial bloodstream infection was documented in 10 patients (27%). Five patients developed bacteremia before and five after engraftment. CMV antigenemia developed in 13 patients (36%). All of the patients responded to pre-emptive use of ganciclovir without developing symptomatic CMV disease.
Concerning fungal infection, two of the 36 evaluable patients developed invasive aspergillosis during the treatment of chronic GVHD, and one developed Candida glabrata infection. Six patients, who had had a history of invasive fungal infection, including invasive pulmonary aspergillosis (n ¼ 5) and Candida abscess, were enrolled in our study but fungal infection did not recur in any of these six patients.
GVHD
Of the 35 patients who achieved donor engraftment and survived more than 21 days, 17 (48%) developed grade II-IV acute GVHD at a median of day 48 (range 21-98). GVHD was rated as grade II in nine, grade III in seven, and grade IV in one. None of the eight patients who received ATG developed grade II-IV acute GVHD. In contrast, 17 of the 27 patients who did not receive ATG developed grade II-IV acute GVHD. This difference was statistically significant (Po0.01). A total of 11 patients with acute GVHD responded to the administration of methylprednisolone. GVHD was refractory to corticosteroid in four patients, of whom one was successfully treated with additional mycofenolate mofetil. Other died of liver acute GVHD complicated with pneumonia and sepsis.
Of the 33 evaluable patients who achieved durable engraftment and survived more than 100 days, 27 developed chronic GVHD. Limited and extensive forms were found in five and 22 patients, respectively. Extensive forms were preceded by acute GVHD in 15 patients. Respiratory disorder-associated chronic GVHD was observed in four patients (two bronchiolitis obliterans, two bronchiolitis obliterans with organizing pneumonia). Two died of colon GVHD complicated systemic infection.
Disease response and relapse
All of the 15 patients with AML who were in remission at transplantation had sustained durable remission, although three patients have relapsed. While one patient with refractory MDS-AML developed engraftment failure because leukemic cells could not be eradicated by the preparative regimen, 14 of the 15 patients with measurable disease achieved remission after RIST, of whom four relapsed. Five MDS-RA patients achieved durable engraftment and remission, and one presented late graft failure.
We treated 14 patients with low-risk myeloid malignancy with one developing disease progression after transplant (Table 3 ). In contrast, 21 high-risk patients engrafted and six relapsed at a median of 282 days (78-728) after transplant. The difference was not significant (P ¼ 0.11). The outcomes of patients with high-risk disease are shown in Table 4 . All of the five patients who received an ATGcontaining preparative regimen relapsed at a median of 359 days (78-728). The incidences of acute (grade II-IV) and chronic GVHD were 0% (0/5) and 50% (2/4), respectively. On the other hand, one of 16 patients who did not receive an ATG-containing regimen relapsed on day 205 after transplant. The incidences of acute (grade II-IV) and chronic GVHD were 62% (10/16) and 94% (15/16), respectively. Median follow-up in the ATG and non-ATG groups was 838 days (347-1271) and 361 days (108-901 days).
Clinical courses after relapse of high-risk group are shown in Table 4 . Patient 1 responded to DLI. Patient 2 had achieved CR following re-induction chemotherapy, but 
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T Hamaki et al relapsed again. Therefore, she received a second RIST from an HLA one-antigen mismatched alternative family donor, but died of multiple organ failure 29 days after the second transplant. Two patients (patients 5 and 7) had sustained CR following a second RIST using the same donor. However, patient 5 died from complication associated with chronic GVHD. Patient 7 relapsed 8 months after second RIST and died. Patient 10 received chemotherapy alone and died from progressive disease. Patient 18 did not respond to chemotherapy, but cleared blasts from bone marrow following a second RIST with the same donor, although she developed graft failure thereafter. She received a third transplantation with cord blood stem cells. Although one patient (patient 2) received ATG because of HLA disparity, ATG was not included in the preparative regimens in the second or third transplantation in the remaining four patients. In the low-risk group, patient 17 with MDS RA developed RAEB after remission. She is alive with receiving supportive chemotherapies.
Disease-free and overall survival
As of April 20, 2003, 24 patients were alive for 4.4-43.5 months after transplantation, with a median follow-up of 12.4 months. A total of 12 patients died during the study period (patients 2, 5, 6, 7, 9, 10, 11, 15, 16, 22, 30, and 34). Four died of disease progression including multiple organ failure following the second RIST. Six patients died of complications including systemic infection, colon GVHD, and respiratory dysfunction associated with GVHD. One died of recurrence of interstitial pneumonia. The other died of secondary metastatic liver adenocarcinoma. The Kaplan-Meier estimated 1-year OS in the lowand high-risk groups was 85% (95% CI 66-100%) and 80% (95% CI 62-98%), respectively (not significant; P ¼ 0.98) (Figure 1a) . Estimated 1-year DFS was 85% (95% CI 66-100%) and 64% (95% CI 42-86%), respectively (Figure 1b ). These differences were not significant (P ¼ 0.59).
Discussion
This is a small pilot study from which it is difficult to draw a definitive conclusion on the usefulness of RIST for myeloid malignancies. However, regarding the primary end point, we achieved complete chimerism without early transplant-related mortality in 29 of the 32 evaluated patients. Only one patient developed primary graft failure with persistent leukemic cells after the preparative regimen. Notably, serial chimerism analysis revealed that half the patients achieved complete chimerism without DLI by day 28 after transplantation and most achieved complete chimerism by day 90. Bornhauser et al 23 reported early induction of complete chimerism using a regimen consisting of fludarabine/busulfan, which is similar to ours. These findings were in contrast to those in previous studies with different combination regimens. 24 When primary malignant diseases are refractory or beyond salvage therapy, it is widely believed that a nonmyeloablative preparative regimen is insufficient to establish stable engraftment. Giralt et al reported 35 patients with AML or MDS who were treated with purine analog, cytarabine, and idarubicin followed by allogeneic HSCT from an HLA-identical or one-antigen mismatched sibling donor. Two of the 23 evaluable patients failed to achieve initial engraftment, and two patients with 490% engraftment had late autologous reconstitution by 3 months without evidence of relapse. Four of the 35 patients were finally diagnosed with graft failure. 12 Childs et al 24 investigated the kinetics of donor chimerism after RIST using the fludarabine/cyclophosphamide regimen. Complete donor chimerism was achieved more slowly, and DLI was occasionally required in their study. Thus, our busulfan-containing reduced-intensity preparative regimen appears to be beneficial for achieving early and sustained engraftment.
In this study, the nonrelapse mortality rate within 100 days of transplantation was 2.7%, which was much lower than those reported in previous studies on RIST or conventional HSCT.
2,13 According to Bearman et al's criteria, 21 only one patient developed grade III-IV regimen-related toxicities, which were difficult to distinguish from the pre-transplant physical condition and a septicemia episode. Since the dose-limiting toxicity of busulfan in the setting of high-dose chemotherapy with HSCT is hepatic veno-occlusive disease, 25 hepatic dysfunction was frequently observed in this study. However, in this study, most of the hepatic damage was mild to moderate, and was rated as grade I (n ¼ 11) or grade II (n ¼ 9). None of the patients developed veno-occlusive disease of the liver during their clinical course. This study demonstrates that the combination of purine analog and 8 mg/kg busulfan is feasible for use in elderly patients or those with organ dysfunction.
Both fludarabine and cladribine have potent immunosuppressive and mild myeloablative effects. 26, 27 The nonhematological toxicities of these agents are mild to moderate, while neurotoxicity sometimes develops at higher than the recommended dose. 28 However, Giralt et al 13 reported severe renal toxicity in patients receiving a cladribine-containing preparative regimen. In their study, fatal regimen-related toxicity, mostly renal toxicity, developed in four of eight patients, leading to the early closure of this treatment arm. They noted that the synergistic effects of melphalan and cladribine might cause toxic effects on the kidney. Based on their report, 13 we decreased the dose of 2-CdA to 0.11 mg/kg for 6 days, which was equal to the dose used in the single-agent treatment of lymphoid malignancies, 14 and approximately half of that used by Giralt et al. 13 In this study, seven of the eight patients who received a cladribine-based preparative regimen achieved sustained engraftment without developing grade III-IV regimen-related toxicities, although one patient with infectious complications developed late graft failure. Hence, this study suggests that a reduced dose of 2-CdA is sufficient for sustained engraftment, and may partly explain the lower toxicity than that reported by Giralt et al.
13
The balance between GVHD and GVL is a significant issue in RIST. Since it has been hypothesized that the cytokine release caused by RRT enhances acute GVHD, 29 the use of a reduced-intensity preparative regimen may reduce the incidence of GVHD. However, we did not see any meaningful difference in the incidence of GVHD with a conventional transplant, within the context of RIST. [30] [31] [32] In this study, the incidences of grade II-IV acute and chronic GVHD were 43 and 82%, respectively. RIST is immunotherapy. It is difficult to separate GVL from GVHD. Martin et al 33 suggested the clinical grading of system of acute GVHD that represented a categorization of clinical management. Although some treatment protocols often specify 'grade II' GVHD as an indication for treatment, clinical management decisions actually entail evaluation of many risk factors in addition to overall severity. They suggested that treatment could be deferred even in patients with grade III GVHD, because GVHD was permissive and tolerable when risk factors were absent. Therefore, we often withheld the administration of steroids for GVHD if the patient was generally well. However, the GVHD-related mortality of 11% was lower than for CST, with the limited numbers of patients evaluated in this study. These findings suggest that GVHD is still a significant problem in RIST, and that RIST can exert a GVL effect as well as CST.
Considering that augmentation of GVHD prophylaxis might hamper the GVL effect and that malignant cells cannot be eradicated by a reduced-intensity preparative regimen alone, we should be careful in the management of GVHD in RIST.
Until November 2000, 10 patients (five low risk, five high risk) had received ATG-containing regimens to harness stable engraftment.
14 Based on the report by Bornhauser et al 23 that ATG is not essential for engraftment in RIST, we excluded ATG from preparative regimens in December 2000. Since ATG has a long half-life in humans, 34 it can deplete both host-derived and donor-derived T lymphocytes, and inhibits not only graft rejection but also GVHD. As of December 2002, 26 patients (nine low risk, 17 high risk) had received a preparative regimen consisting of fludarabine and busulfan. Concerning the low-risk group, one of the 14 patients relapsed during the study periods with a median follow-up of 319 days (range 78-1010). Acute and chronic GVHD developed in six and eight patients, respectively. All five high-risk patients who had received ATG relapsed without developing grade II-IV acute GVHD. In contrast, nine and 15 of the 17 patients who had not been given ATG, with a median follow-up of 374 days (range 108-1271), developed grade II-IV acute and chronic GVHD, respectively. Only one patient relapsed.
The development of GVHD may not be associated with the control of low-risk myeloid malignancies. GVHD and infection, rather than relapse, are more important problems to be addressed in these patients. Indeed, our study showed that two in the low-risk group died of systemic complications associated with extensive GVHD. One developed lethal bronchiolitis obliterans as a manifestation of chronic GVHD. Adequate management for GVHD based on risk of primary disease may be required. Augmentation of GVHD prophylaxis such as with CAMPATH-1H, 35 ATG, mycofenolate mofetil, 36 tacrolimus, 37 and methotrexate 37 may be an option. We are now conducting a prospective randomized trial comparing cyclosporine alone with cyclosporine and short-term methotrexate as GVHD prophylaxis in RIST for low-risk hematological malignancies. Furthermore, it should be noted that none of the lowrisk patients with a median age of 58 relapsed in this study.
Since the genetic backgrounds of myeloid leukemia tended to be worse in elderly patients, 38 these findings support the feasibility of applying RIST in young patients with low-risk myeloid malignancies. It is possible that RIST will also be beneficial in young patients, since organ damage including infertility seems to be mild and less frequent in RIST than in CIST. A prospective randomized controlled trial comparing RIST with CST in young patients is warranted.
This study showed that some patients in the high-risk group can expect long-term survival following RIST, and that relapse-free survival is associated with the development of GVHD. However, it is difficult to differentiate a GVL effect from GVHD. The induction of GVHD through early tapering of cyclosporine may improve survival. 39, 40 Severe, sometimes fatal, GVHD will be unavoidable in some patients. However, such a strategy will be justified considering the poor prognosis of elderly patients with chemorefractory myeloid malignancies. 41 In the future, tumor vaccination against leukemia-specific antigen 42 or adoptive transfer of cytotoxic T cells against minor antigens 43 will be a choice for these patients. Some animal and human studies have shown a strong anti-leukemia effect without causing GVHD. 43 In conclusion, although the number of patients is small and the follow-up is short, our results show that purine analog-based RIST can produce durable engraftment, lower TRM, and a high response rate in patients with advanced myeloid malignancies. These observations provide a rationale for continuing our clinical trials, which should be modified to focus more on minimizing toxicities, preserving a GVL effect, and establishing optimal strategies for GVHD prophylaxis according to the risk of the primary diseases.
